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sics, the currently available information is not sufficient toRelationship between nonphenacetin combined analgesics and
postulate a harmful toxicological effect.nephropathy: A review.
Conclusion. The committee’s two main conclusions wereBackground. The debate on the association between non-
that sufficient evidence is absent to associate nonphenacetinphenacetin-containing combined analgesics and renal disease
combined analgesics with nephropathy and that new studieshas lasted for several years.
should be done to provide appropriate data for resolving theMethod. A peer review committee of scientists, selected
question.jointly by the regulatory authorities of Germany, Switzerland,
and Austria and the pharmaceutical industry was asked to
critically review data on the relationship between nonphenace-
tin combined analgesics and nephropathy. The association between nonphenacetin-containing
Results. The committee regarded epidemiologic evidence on
combined analgesics and renal disease has been debatednonphenacetin combined analgesics as inconclusive because of
for several years. In previous studies of humans, thesparse information and substantial methodological problems.
main focus was on end-stage renal disease (ESRD), andThe committee also noted that a diagnosis of analgesic-associ-
ated nephropathy (AAN) in clinical practice usually depends no analytical study has examined analgesic-associated
on information about exposure before or in the early stages nephropathy (AAN) specifically or analyzed it separately
of the disease and is seldom accompanied by specific histologic regarding nonphenacetin-containing combined analgesics.evidence. The morphologic finding of papillary calcification
Despite considerable clinical, pathological, and epide-can arise from other conditions and is not specific for AAN.
miological research, many open questions remain. Al-For these reasons, the identification criteria for AAN should be
reappraised with scientific methods to validate the diagnostic though the association with phenacetin is established,
procedure. In the limited amount of experimental pharmaco- the primary question today is whether the modern, non-
logical data in humans and animals, the committee found no phenacetin-containing analgesics are also associated with
convincing evidence to confirm or refute the hypothesis that ESRD or AAN or whether any apparent associations arenonphenacetin combined analgesics are more nephrotoxic than
caused by past use of phenacetin.single formulations. For caffeine taken with combined analge-
These questions have recently evoked considerable
media attention in Germany, Austria, and Switzerland,
where various groups have demanded protective regula-Key words: end-stage renal failure, analgesic-associated nephropathy,
combined analgesics, nonphenacetin analgesics, renal toxicity. tory action. As a result, the Federal Drug Authorities
of those countries asked the pertinent members of theReceived for publication January 7, 2000
pharmaceutical industry to support a special ad hoc re-and in revised form July 11, 2000
Accepted for publication July 12, 2000 view of the available literature and evidence. The mem-
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the authorities and the industry. The industry gave an however, has some important methodological problems.
Unfortunately, the investigators identified the commer-unconditional grant to the organizers to prepare and
execute the meeting, which occurred on June 28–29, cial combinations by brand names only, without distin-
guishing the changing ingredients of each brand during1999, in Potsdam, Germany. The meeting was also at-
tended by observers from the regulatory authorities and the period before 1983. Because the analyses did not
account for the fact that brand-name products generallyfrom the industry.
contained phenacetin before 1983, it is difficult or impos-
Objectives sible to differentiate the actual constituents of the com-
bined agents and to separate the effects of phenacetinThe main question to be answered was whether the
literature contained sufficient evidence to conclude that and nonphenacetin combinations. The review committee
also noted several other methodological weaknesses,combined nonphenacetin-containing analgesics cause
nephropathy. A subsidiary question was whether scien- such as the possible noncomparability of the exposed
and unexposed cohorts at baseline, problems in identi-tific evidence exists to show that the combination of
analgesic drugs with caffeine increases nephrotoxicity or fying the duration and time since first use of analgesics,
and the lack of information on the history of comorbiditycontributes to habituation and abuse of analgesic drugs.
A secondary objective of the meeting was to identify and comedication and on indications for use of analge-
sics. For example, no information was given about pre-additional pertinent questions and to make recommen-
dations for further research, if appropriate. existing renal diseases with normal renal function (or
relevant therapy) that might differ among the exposed
and unexposed groups, thereby explaining subsequent
METHODS
differences in results.
The committee reviewed information from different Because of the methodological weaknesses, the com-
sources: peer-reviewed papers, editorials, abstracts, and mittee disagreed with the authors’ conclusion that “all
any other pertinent publications, including those in the cases developing renal impairment abused analgesic
books and supplements to journals. The particular scien- mixtures of varying composition suggesting once more
tific issues considered during the appraisal were as fol- that only by limiting the availability of all kinds of analge-
lows: (1) quality of the diagnostic criteria for “analgesic sic mixtures a decrease in the occurrence of this disease
nephropathy” in pathological and radiological manifes- can be obtained” [1]. The committee concluded that all
tations, (2) objectivity and accuracy of the identification of the drug abusers cited by Elseviers and De Broe may
of past exposure to analgesics, (3) objectivity and accu- have used phenacetin at some time in their history, and
racy of the selection and definition of cases of “nephropa- therefore, the data presented do not address the question
thy,” and (4) appropriateness of the data analyses. of whether nonphenacetin-containing combined analge-
sics are associated with a higher risk of renal failure.
In the case-control study of Pommer et al, done in 1984RESULTS
through 1986, 517 cases (patients on renal replacement
Epidemiologic studies therapy in whom a careful history of analgesic intake was
The available epidemiologic research could be divided collected) were matched to the same number of controls
into analytic (cohort or case control) and ecologic studies. [3]. An increased risk of ESRD was found to be associ-
Analytic studies. In a thorough literature search be- ated with the use of more than 0.1 kg phenacetin-con-
fore the committee meeting, only nine analytic epidemio- taining analgesic substances, with an increasing risk for
logic studies could be identified that contained original increasing dose. In general, an increased risk of nephrop-
research dealing with the association between nephropa- athy was found with intakes of .0.5 kg analgesic sub-
thy and use of various analgesics. Table 1 shows the anal- stances in most of the combination drugs. The odds ratio
gesic agents examined in those nine studies [1–9]. The was 4.83 (95% CI, 2.70 to 8.76) for 60 analgesic doses—
review committee concluded that only four [1, 3–5] of including phenacetin—taken monthly for more than five
these studies were pertinent for estimating the effects of years. The pertinent exposures occurred in 65 cases and
combined nonphenacetin analgesics, because the other 18 controls.
studies did not specifically analyze the effect of analgesic One strength of the Pommer et al study is that the
formulations containing more than one ingredient. brand names of all analgesics were recorded and that
The cohort study by Elseviers and De Broe followed the contents of different ingredients were identified at
a group of 200 abusers of various analgesic formulations different periods in time. The case selection, however,
and 200 nonanalgesic-using controls for seven years to seemed to include a nonhomogeneous group of preva-
see differences in renal function [1]. At the end of the lent (longer history of end-stage renal failure) and inci-
observation period, a significant decrease of renal func- dent (newly developed end-stage renal failure) cases,
and the investigators did not report evidence to showtion was found in 12 abusers versus 2 controls. The study,
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Table 1. Analytic epidemiologic studies of nephropathy and diverse analgesicsa
Measure of association estimated for
Nonphenacetin
First author Phenacetin combinations Other analgesics NSAIDs
Cohort studies
Elseviers [1] ? ? Not specified 2
Dubach [2] 1 2 ASA 2
Case-control studies
Pommer [3] 1 1 Multiple 2
Morlans [4] 1 1 PYR, ASA 2
Murray [5] 1 1 ACET, ASA 2
McCredie [6] 1 2 ACET 2
Sandler [7] 1 2 ACET, ASA 1
Steenland [8] 1 2 — 2
Perneger [9] 2 2 ACET., ASA 1
Symbols are: 1, included in the study; 2, not investigated; ?, could not be determined, for reasons cited in the accompanying text. Abbreviations are: ASA, acetyl-
salicylic acid, aspirin; ACET, acetaminophen, paracetamol; NSAIDs, nonsteroidal anti-inflammatory drugs; PYR, pyrazolone.
a For more details, see critical reviews by Delzell E, Shapiro S: A review of epidemiologic studies on nonnarcotic analgesics and chronic renal disease. Medicine
77:102–121, 1998; and McLaughlin JK, Lipworth L, Wong-Ho C, Blot WJ: Analgesic use and chronic renal failure: A critical review of the epidemiologic literature.
Kidney Int 54:679–686, 1998.
that the risk estimates from the prevalent and incident Morlans et al found that the risk for ESRD development
was significantly increased with overall analgesic expo-cases are similar enough to permit their pooling. An
additional problem is that the control group contained sure (OR 2.89, 95% CI, 1.78 to 4.68), markedly increased
with phenacetin-containing combinations (OR 19.05,an ill-defined collection of university clinic patients, usu-
ally a highly selected group, which may not represent 95% CI, 2.31 to 157.4), significantly increased for users
of acetylsalicylic acid (OR 2.54, 95% CI, 1.24 to 5.20),the same population from which the cases emerged. A
separate problem was the study’s low statistical power and nonsignificantly elevated for pyrazolones (OR 2.16,
95% CI, 0.87 to 5.32) [4]. No estimates of risk wereto evaluate the independent risk of nonphenacetin-con-
taining combined analgesics. The number of persons who presented for the aspirin-paracetamol combination.
On the other hand, Murray et al did not find an ele-regularly used combined analgesics without past use of
phenacetin was small: 54 cases and 59 controls (28 and vated risk that was statistically significant for either com-
bined analgesics or for phenacetin [5]. The odds ratios24 with a relevant dose of .0.5 kg analgesic substance).
The results do not indicate, but cannot rule out, a signifi- and 95% confidence intervals for all combinations, com-
binations of aspirin/paracetamol, and aspirin/phenacetincantly increased risk of nephropathy in the absence of
phenacetin use. were, respectively: 1.32 (95% CI, 0.8 to 2.1), 1.86 (95%
CI, 0.8 to 4.6), and 1.01 (95% CI, 0.6 to 1.7). No combina-In bivariate analyses, the use of combined analgesics
coformulated with caffeine (irrespective of past use of tion was found to be significantly related to ESRD devel-
opment. The study, however, had small numbers of casesphenacetin) showed an increasing risk of ESRD with
increasing dose of analgesic substance. The peak odds and controls who used the aspirin-paracetamol combina-
tion, and the data for this combination were not analyzedratio of 52.56 (95% CI, 6.83 to 402.78) was reached for
an intake of 1.25 kg caffeine in the combinations. These for a dose–response relationship. A significantly increas-
ing trend in risk with the increasing dose (or durationhigh odds ratios are difficult to evaluate, however, be-
cause the investigators did not check for the possibility of of use) could indicate an increased risk, even if results for
the individual dose categories are nonsignificant. Suchconfounding. The elevated odds ratios for combinations
containing higher doses of caffeine could be explained trends were shown, however, only for phenacetin in cu-
mulative doses or combinations.by high doses of analgesics being associated with high
doses of caffeine and past use of phenacetin. Ecologic studies. In ecologic studies, individual sub-
jects are not examined. Instead, general population dataPommer et al concluded that “over-the-counter mixed-
compound analgesics, particularly those that contain caf- for the prevalence or incidence of a disease are corre-
lated across regions with data for sales or general usefeine, should be banned or at least no longer made avail-
able without a prescription. Over-the-counter sales should of a suspected etiologic agent. Although often used to
generate hypotheses, ecologic studies provide, at best,be restricted to single-ingredient analgesics in small
packages only” [3]. The committee disagreed with this weak evidence on causation. In contrast to analytic epi-
demiological studies, no information is available aboutconclusion, which did not seem appropriately supported
by the data. the disease, exposure (suspected agent), and important
confounders in individual persons.In one of the other two pertinent case-control studies,
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The ecologic study by Elseviers and De Broe found mainly by past exposure to phenacetin. Although these
data have not yet been published, the committee never-an apparently high correlation between the “prevalence”
of analgesic nephropathy in dialysis units and the associ- theless regarded the results as reassuring since they re-
vealed no worsening evolution of new cases of analgesicated local sales of combined analgesics [10]. What was
called “prevalence,” however, was the proportion of nephropathy in a country with free OTC sales of phenac-
etin-free combination analgesics.AAN among dialysis patients, not in the general popula-
tion. These “prevalence” data were correlated with the From the currently available epidemiological evidence,
the committee decided that both the analytic and eco-combined sales of three different analgesics: Perdolan,
Mann, and Witte Kruis. All three had contained phenac- logic types of studies are inconclusive about the relation-
ship between combined nonphenacetin analgesics andetin. The correlations were not adjusted for the duration
in which phenacetin had remained in each formulation. the occurrence of nephropathy. No epidemiological data
were found to support or refute the hypothesis that com-The ecologic results can equally be explained by
changes in the occurrence of AAN after withdrawal of bined nonphenacetin analgesics, when coformulated with
caffeine, elevate the risk of nephropathy. Finally, thephenacetin from the market, and not by regulation of the
over-the-counter (OTC) availability of nonphenacetin- epidemiological studies contained very little useful infor-
mation on abusers of analgesics.containing mixed analgesics. The underlying problem
arises because regulatory withdrawal of a drug from the
Methodologic issuesOTC market will reduce the number of newly exposed
subjects without immediately altering the already ex- The committee’s methodological discussion focused
on temporal changes in the indications for dialysis, onposed population, which enlarges with time. A long lag
time between exposure and occurrence of the disease the reliability of histories of drug use, and on the accuracy
of the clinical diagnosis of analgesic nephropathy.could be demonstrated with only age-stratified analyses
over a series of time periods (the expectation would Temporal changes in the indication for dialysis are
crucial in understanding the results of the ecologic stud-be declining incidence in younger age groups and more
stable incidence of AAN with increasing age). Such data, ies. An increasing proportion of dialysis patients in higher
age groups would also increase the number of patientshowever, were not provided and discussed.
In reviews in the New England Journal of Medicine with apparent AAN, and they would have been exposed
long before any regulatory measures were taken.[11] and the American Journal of Kidney Disease [12],
patients not taking phenacetin were said to have devel- Because the indications for dialysis have substantially
changed during the past few decades, trend analyses ofoped AAN, but the information used in the reviews
seems to have come from uncontrolled case series; our crude prevalence rates for AAN among dialysis patients
are difficult to interpret. At the very least, they shouldcommittee was unable to find the original data for those
two reviews reported either consistently or in peer- be presented and appraised as age-specific proportions of
AAN among those admitted for treatment. The possiblereviewed journals.
In a separate report, Michielsen and De Schepper multifactorial etiology of ESRD attributed to AAN re-
quires that the analyses of analgesic use consider a life-presented data showing similar time trends for the pro-
portion of incident cases of AAN among patients starting long history of onset, duration (dose), and types of anal-
gesic as well as coexposures, medical conditions, anddialysis in Australia (where combined analgesics were
banned from the OTC market in 1979) and Belgium many other potential confounding variables. These fac-
tors have not been adequately considered in previous(where combined analgesics are still available as OTC
drugs) between 1970 and 1998 [13]. At the meeting of analytical studies.
In clinical practice, a specific diagnosis of AAN is al-our committee, Michielsen also showed currently unpub-
lished data on time trends of AAN occurrence in patients most never accompanied by histologic evidence and is
usually based on information about exposure before orstarting dialysis and in the population of Flanders (Bel-
gium) and in New South Wales (Australia). In these two in the early stages of the disease. Papillary calcification
may occur as a result of other conditions and is notregions with an apparently high occurrence of AAN, the
trends per million population were almost identical, and specific for AAN [14]. Thus, identification criteria for
AAN should be reappraised with scientific methods thatthey showed, despite different legislation regarding the
availability of nonphenacetin combination analgesics, a validate the diagnostic tests, independently of exposure
information.similar decline in the overall proportions (1970–1998)
and in the age-specific incidence per million population In addition, having recently published on morphologi-
cal issues in analgesic nephropathy [15], Mihatsch, Brun-of AAN among patients admitted to dialysis (1984–1997).
The age-specific incidences declined in patients under ner, and Gloor pointed out that a specific morphological
lesion—suburothelial capillary sclerosis—is present only55 years and were less altered in patients over 65. This
would be the expected change if the AAN is caused for phenacetin-related nephropathy. Although Mihatsch,
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Table 2. Unresolved issues
• Comparative nephrotoxicity of specific analgesic agents, other than those containing phenacetin.
• Dose-response relationships.
• Types of renal disease possibly caused by analgesics.
• Cofactors (including caffeine) possibly related both to analgesic use and to the development of chronic renal disease.
• Pathological mechanisms of analgesic-induced chronic renal disease in humans.
Brunner, and Gloor had not observed such a lesion in effect is not well documented in animals. The alleged
mechanism by which salicylates inhibit the pentose phos-patients who abuse paracetamol, they included paraceta-
mol in their list of potential causes of capillary sclerosis phate shunt has been documented only for high concen-
trations in vitro and has been cited in only a single pub-because Nanra, in a personal communication, said he
had seen such patients. Mihatsch, Brunner, and Gloor lished abstract (abstract; Goldberg et al, J Clin Invest
50:37a, 1971). Humans given paracetamol for two con-also confirmed that capillary sclerosis has not yet been
reproduced in animal studies and that animals seem inad- secutive days showed no indication of a potentiating
effect on the inhibition of prostaglandin synthesis byequate as models for the AAN seen in humans.
The committee recognized that papillary necrosis has acetylsalicylic acid (ASA) [19]. It seems obvious that
these sparse in vitro data do not constitute a basis tocauses other than analgesic abuse and that if it is diag-
nosed by ultrasound or computed tomography scan, the support the assumption of a special synergistic medullary
toxicity of paracetamol plus acetylic acid.result is consistent with AAN but lacks specificity. Mi-
hatsch emphasized that early forms of papillary necrosis The committee also evaluated the possibility of a spe-
cial nephrotoxic effect by caffeine-containing mixed an-are often undiagnosed until calcification appears. In an
autopsy study 20 years ago, they found that only 50% algesics without phenacetin. Because the evidence from
the only available epidemiological study [3] was not per-of the AAN cases were clinically suspected, but 137 of
141 patients had capillary sclerosis at a time when phen- suasive, the data were reviewed from a pharmacological
perspective. Long-term toxicological studies [20], carci-acetin was commonly used (abstracts; Mihatsch et al,
Kidney Int 17:412 and 859, 1980). A modern repetition nogenicity studies [21, 22], and animal experiments try-
ing to induce analgesic nephropathy [23] did not show anof this autopsy study would be desirable.
Several unresolved issues were identified during the dis- additional nephrotoxic effect when caffeine was added to
combined analgesics. (The issue of caffeine habituationcussion (Table 2). These issues should be kept in mind
when new epidemiological studies are designed or planned. or dependence was deferred for a separate later review
that is reported elsewhere [24].)
The committee concluded that the currently available
EXPERIMENTAL
evidence does not allow a special harmful toxicologicPHARMACOLOGIC EVIDENCE
effect to be postulated for analgesics combined with caf-
The generally accepted hypothesis for the mechanism feine. Furthermore, the limited amount of experimental
of acute hepatic and renal cortical toxicity is that paracet- pharmacologic data in humans and animals offers no
amol is oxidized by an enzyme system that is not present convincing evidence that nonphenacetin combined anal-
in the medulla [16]. Therefore, this mechanism is not ap- gesics are either as safe as or more nephrotoxic than
plicable as a cause of AAN. For medullary toxicity of single formulations.
paracetamol, the other hypotheses involve mainly co-oxi-
dation during the reduction of arachidonic acid-derived
CONCLUSIONShydroperoxides [17, 18]. These hypotheses essentially
depend on data (some unpublished) obtained in vitro in The main conclusion of the committee was that there
is insufficient evidence to claim that combined analgesics,cell-free systems in the absence of cell compartmentaliza-
tion, competing enzymes, and substrates and in the pres- in the absence of phenacetin, are causally associated with
nephropathy. The committee also recommended that aence of high concentrations of externally added sub-
strates or inhibitors that do not exist in vivo. Thus, the new epidemiological study is needed to address this ques-
tion and that the study be done, for completion in abouthypotheses for the medullary toxicity of paracetamol and
its increased toxicity in the presence of salicylate are three to four years, in the countries where regulatory
authorities are most concerned about a potential risklargely unverified extrapolations to humans from artifi-
cial in vitro systems. of nonphenacetin combined analgesics. The design and
manual of operations for such a study was discussed atThe essential cofactor of a suggested synergistic toxic-
ity of paracetamol plus salicylates is the depletion by a subsequent meeting of the review group in the spring
of 2000.salicylate of glutathion in the renal medulla, but this
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